George Badescu

Company: Heidelberg Pharma

Job title: Chief Business Officer

Seminars:

12:00pm Overcoming Tumor Resistance With Amanitin-Based ADCs – Insights From the Clinic 12:00 pm

Discussing the trends and advantages of dual-payload ADCs to combat resistance Overviewing dual-payload ADCs generated from the co-Nectar platform Sharing HoneyBear Biosciences portfolio of dual-payload ADCs, and future plansRead more

day: Day One Preclinical & Clinical Development Track

12:00pm Panel Discussion: What is the Next Frontier Within ADC Payloads? 12:00 pm

What are the emerging trends in ADC payloads in APAC, the US and Europe? Exploring the most novel MOAs that are entering preclinical development and the value proposition of each compared to tubulin inhibitors and DNA damaging agents Considering the difference in physicochemical properties and PK profiles of next generation versus traditional ADC payloadsRead more

day: Day Two Discovery Track